KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short term Debt (2019 - 2025)

Historic Short term Debt for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $380.0 million.

  • Royalty Pharma's Short term Debt fell 6191.52% to $380.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $380.0 million, marking a year-over-year decrease of 6191.52%. This contributed to the annual value of $380.0 million for FY2025, which is 6191.52% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Short term Debt is $380.0 million, which was down 6191.52% from $380.0 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Short term Debt ranged from a high of $999.4 million in Q2 2025 and a low of $107.9 million during Q4 2021
  • For the 5-year period, Royalty Pharma's Short term Debt averaged around $589.4 million, with its median value being $688.3 million (2022).
  • As far as peak fluctuations go, Royalty Pharma's Short term Debt soared by 82418.7% in 2022, and later crashed by 6191.52% in 2025.
  • Royalty Pharma's Short term Debt (Quarter) stood at $107.9 million in 2021, then surged by 824.19% to $997.5 million in 2022, then increased by 0.19% to $999.4 million in 2023, then decreased by 0.16% to $997.8 million in 2024, then crashed by 61.92% to $380.0 million in 2025.
  • Its Short term Debt was $380.0 million in Q4 2025, compared to $380.0 million in Q3 2025 and $999.4 million in Q2 2025.